SCHEMBL6226752

SCHEMBL6226752

NCC(=O)Nc1ccc(Cl)cc1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.57
GABRD O14764 2/20 0.57
GABRA1 P14867 2/20 0.57
GABRB1 P18505 2/20 0.57
GABRG2 P18507 2/20 0.57
GABRB3 P28472 2/20 0.57
GABRA5 P31644 2/20 0.57
GABRA3 P34903 2/20 0.57
GABRA2 P47869 2/20 0.57
GABRB2 P47870 2/20 0.57
GABRA4 P48169 2/20 0.57
GABRE P78334 2/20 0.57
GABRA6 Q16445 2/20 0.57
GABRG1 Q8N1C3 2/20 0.57
GABRG3 Q99928 2/20 0.57
GABRQ Q9UN88 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.53
KDM4E B2RXH2 2/20 0.53
CYP1A2 P05177 1/20 0.53
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391455 0.84 CA1 (0.65) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL38661880 0.81 HDAC1 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5103850 0.81 MEN1 (0.54) KDM4EMAPTSMN1; SMN2HDAC1MEN1
SCHEMBL3953891 0.80 HDAC1 (0.55) KDM4ESMN1; SMN2HDAC1MEN1KMT2A
SCHEMBL9651918 0.79 HDAC1 (0.70) KDM4EMAPTSMN1; SMN2CA1CA2
SCHEMBL29904755 0.79 HDAC1 (0.70) KDM4EMAPTSMN1; SMN2CA1CA2
SCHEMBL27736941 0.79 KDM4E (0.59) L3MBTL1KDM4EHDAC1POLBNPC1
SCHEMBL28304223 0.77 AAK1 (0.47) L3MBTL1KDM4ECA1CA2HDAC1
SCHEMBL15416460 0.75 LMNA (0.57) MAPTSMN1; SMN2HDAC1MEN1KMT2A
SCHEMBL7324248 0.74 GABRP (0.75) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583757-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-10-12 EP disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed